{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:11:01Z","timestamp":1793232661003,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"DOI":"10.1038\/s41591-026-04717-8","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:56:22Z","timestamp":1792014982000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3078-4155","authenticated-orcid":false,"given":"MacLean C.","family":"Sellars","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5334-3240","authenticated-orcid":false,"given":"Jessica A.","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohoon","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Vanasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9059-6335","authenticated-orcid":false,"given":"Ruolin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cleo","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe R.","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyohei K.","family":"Tabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Kowelewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Chun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7726-9352","authenticated-orcid":false,"given":"Pia","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9651-4288","authenticated-orcid":false,"given":"Andjela","family":"Crnjac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9277-086X","authenticated-orcid":false,"given":"Haley E.","family":"Sax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipheaviny","family":"Chea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0887-8482","authenticated-orcid":false,"suffix":"3rd","given":"J. Thomas","family":"Janes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micah","family":"Rickles-Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6133-0164","authenticated-orcid":false,"given":"Amit","family":"Sud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savni","family":"Sarolkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Olive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley","family":"Greenslade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Cibulskis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Hacohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8412-5665","authenticated-orcid":false,"given":"Edward F.","family":"Fritsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9106-6141","authenticated-orcid":false,"given":"Shuqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9105-5856","authenticated-orcid":false,"given":"Kenneth J.","family":"Livak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6088-167X","authenticated-orcid":false,"given":"Nabihah","family":"Tayob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6578-3216","authenticated-orcid":false,"given":"Elizabeth H.","family":"Stover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Krasner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Matulonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0936-0753","authenticated-orcid":false,"given":"Gad","family":"Getz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7435-5603","authenticated-orcid":false,"given":"Giacomo","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4253-943X","authenticated-orcid":false,"given":"Patrick A.","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3906-1663","authenticated-orcid":false,"given":"Jeremy M.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4555-2485","authenticated-orcid":false,"given":"Viktor A.","family":"Adalsteinsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8496-6181","authenticated-orcid":false,"given":"Derin B.","family":"Keskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1032-1479","authenticated-orcid":false,"given":"Panagiotis A.","family":"Konstantinopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3348-5054","authenticated-orcid":false,"given":"Catherine J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"key":"4717_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa020177","volume":"348","author":"L Zhang","year":"2003","unstructured":"Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203\u2013213 (2003).","journal-title":"N. Engl. J. Med."},{"key":"4717_CR2","doi-asserted-by":"publisher","first-page":"18538","DOI":"10.1073\/pnas.0509182102","volume":"102","author":"E Sato","year":"2005","unstructured":"Sato, E. et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl Acad. Sci. USA 102, 18538\u201318543 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4717_CR3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ygyno.2018.11.017","volume":"152","author":"A Varga","year":"2019","unstructured":"Varga, A. et al. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028. Gynecol. Oncol. 152, 243\u2013250 (2019).","journal-title":"Gynecol. Oncol."},{"key":"4717_CR4","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","volume":"33","author":"J Hamanishi","year":"2015","unstructured":"Hamanishi, J. et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 33, 4015\u20134022 (2015).","journal-title":"J. Clin. Oncol."},{"key":"4717_CR5","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S0140-6736(26)00602-1","volume":"407","author":"N Colombo","year":"2026","unstructured":"Colombo, N. et al. Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65\/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study. Lancet 407, 1525\u20131537 (2026).","journal-title":"Lancet"},{"key":"4717_CR6","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research Network.","year":"2011","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609\u2013615 (2011).","journal-title":"Nature"},{"key":"4717_CR7","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1158\/1078-0432.CCR-21-2834","volume":"28","author":"M Liu","year":"2022","unstructured":"Liu, M. et al. Improved T-cell immunity following neoadjuvant chemotherapy in ovarian cancer. Clin. Cancer Res. 28, 3356\u20133366 (2022).","journal-title":"Clin. Cancer Res."},{"key":"4717_CR8","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41568-022-00503-z","volume":"22","author":"LE Kandalaft","year":"2022","unstructured":"Kandalaft, L. E., Dangaj Laniti, D. & Coukos, G. Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation. Nat. Rev. Cancer 22, 640\u2013656 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"4717_CR9","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41586-022-05496-1","volume":"612","author":"I Vazquez-Garcia","year":"2022","unstructured":"Vazquez-Garcia, I. et al. Ovarian cancer mutational processes drive site-specific immune evasion. Nature 612, 778\u2013786 (2022).","journal-title":"Nature"},{"key":"4717_CR10","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.ccell.2021.04.004","volume":"39","author":"M Hornburg","year":"2021","unstructured":"Hornburg, M. et al. Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer. Cancer Cell 39, 928\u2013944 e926 (2021).","journal-title":"Cancer Cell"},{"key":"4717_CR11","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565, 234\u2013239 (2019).","journal-title":"Nature"},{"key":"4717_CR12","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41586-024-08507-5","volume":"639","author":"DA Braun","year":"2025","unstructured":"Braun, D. A. et al. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature 639, 474\u2013482 (2025).","journal-title":"Nature"},{"key":"4717_CR13","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150 (2023).","journal-title":"Nature"},{"key":"4717_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41587-019-0322-9","volume":"38","author":"S Sarkizova","year":"2020","unstructured":"Sarkizova, S. et al. A large peptidome dataset improves HLA class I epitope prediction across most of the human population. Nat. Biotechnol. 38, 199\u2013209 (2020).","journal-title":"Nat. Biotechnol."},{"key":"4717_CR15","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","volume":"199","author":"V Jurtz","year":"2017","unstructured":"Jurtz, V. et al. NetMHCpan-4.0: improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J. Immunol. 199, 3360\u20133368 (2017).","journal-title":"J. Immunol."},{"key":"4717_CR16","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1158\/1078-0432.CCR-19-3005","volume":"26","author":"HA Parsons","year":"2020","unstructured":"Parsons, H. A. et al. Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer. Clin. Cancer Res. 26, 2556\u20132564 (2020).","journal-title":"Clin. Cancer Res."},{"key":"4717_CR17","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jim.2006.07.015","volume":"315","author":"Z Moodie","year":"2006","unstructured":"Moodie, Z., Huang, Y., Gu, L., Hural, J. & Self, S. G. Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials. J. Immunol. Methods 315, 121\u2013132 (2006).","journal-title":"J. Immunol. Methods"},{"key":"4717_CR18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03704-y","volume":"596","author":"G Oliveira","year":"2021","unstructured":"Oliveira, G. et al. Phenotype, specificity and avidity of antitumour CD8(+) T cells in melanoma. Nature 596, 119\u2013125 (2021).","journal-title":"Nature"},{"key":"4717_CR19","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41586-021-03752-4","volume":"596","author":"JX Caushi","year":"2021","unstructured":"Caushi, J. X. et al. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature 596, 126\u2013132 (2021).","journal-title":"Nature"},{"key":"4717_CR20","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ccell.2022.03.008","volume":"40","author":"CM Anadon","year":"2022","unstructured":"Anadon, C. M. et al. Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells. Cancer Cell 40, 545\u2013557 e513 (2022).","journal-title":"Cancer Cell"},{"key":"4717_CR21","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41588-023-01367-1","volume":"55","author":"F Martinez-Jimenez","year":"2023","unstructured":"Martinez-Jimenez, F. et al. Genetic immune escape landscape in primary and metastatic cancer. Nat. Genet. 55, 820\u2013831 (2023).","journal-title":"Nat. Genet."},{"key":"4717_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-023-01154-x","volume":"15","author":"I Filip","year":"2023","unstructured":"Filip, I. et al. Pervasiveness of HLA allele-specific expression loss across tumor types. Genome Med. 15, 8 (2023).","journal-title":"Genome Med."},{"key":"4717_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-59671-3","volume":"10","author":"H Takaya","year":"2020","unstructured":"Takaya, H., Nakai, H., Takamatsu, S., Mandai, M. & Matsumura, N. Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma. Sci Rep. 10, 2757 (2020).","journal-title":"Sci Rep."},{"key":"4717_CR24","doi-asserted-by":"publisher","first-page":"e236","DOI":"10.1016\/j.celrep.2018.03.076","volume":"23","author":"TA Knijnenburg","year":"2018","unstructured":"Knijnenburg, T. A. et al. Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas. Cell Rep. 23, e236 (2018).","journal-title":"Cell Rep"},{"key":"4717_CR25","unstructured":"Broad GDAC Firehose. stddata__2016_01_28 https:\/\/gdac.broadinstitute.org\/runs\/stddata__2016_01_28\/ (Broad Institute of MIT and Harvard, 2016)."},{"key":"4717_CR26","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","volume":"639","author":"Z Sethna","year":"2025","unstructured":"Sethna, Z. et al. RNA neoantigen vaccines prime long-lived CD8(+) T cells in pancreatic cancer. Nature 639, 1042\u20131051 (2025).","journal-title":"Nature"},{"key":"4717_CR27","doi-asserted-by":"publisher","unstructured":"Huber, F. & Bassani-Sternberg, M. Defects in antigen processing and presentation: mechanisms, immune evasion and implications for cancer vaccine development. Nat. Rev. Immunol. https:\/\/doi.org\/10.1038\/s41577-025-01208-8 (2025).","DOI":"10.1038\/s41577-025-01208-8"},{"key":"4717_CR28","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/s41587-024-02420-y","volume":"43","author":"F Huber","year":"2025","unstructured":"Huber, F. et al. A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy. Nat. Biotechnol. 43, 1360\u20131372 (2025).","journal-title":"Nat. Biotechnol."},{"key":"4717_CR29","unstructured":"Blass, E. et al. A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma. Cell (2025)."},{"key":"4717_CR30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nature12222","volume":"499","author":"Cancer Genome Atlas Research Network.","year":"2013","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43\u201349 (2013).","journal-title":"Nature"},{"key":"4717_CR31","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature12912","volume":"505","author":"MS Lawrence","year":"2014","unstructured":"Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495\u2013501 (2014).","journal-title":"Nature"},{"key":"4717_CR32","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-18-0474","volume":"8","author":"SJ Hill","year":"2018","unstructured":"Hill, S. J. et al. Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids. Cancer Discov. 8, 1404\u20131421 (2018).","journal-title":"Cancer Discov"},{"key":"4717_CR33","doi-asserted-by":"publisher","unstructured":"Lee, P. C. et al. Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma. J. Clin. Invest. https:\/\/doi.org\/10.1172\/jci151666 (2022).","DOI":"10.1172\/jci151666"},{"key":"4717_CR34","first-page":"75","volume":"2","author":"DB Keskin","year":"2011","unstructured":"Keskin, D. B. et al. Direct identification of an HPV-16 tumor antigen from cervical cancer biopsy specimens. Front. Immunol. 2, 75 (2011).","journal-title":"Front. Immunol."},{"key":"4717_CR35","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","volume":"42","author":"Y Hao","year":"2024","unstructured":"Hao, Y. et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat. Biotechnol. 42, 293\u2013304 (2024).","journal-title":"Nat. Biotechnol."},{"key":"4717_CR36","doi-asserted-by":"publisher","first-page":"e1009290","DOI":"10.1371\/journal.pcbi.1009290","volume":"17","author":"AA Hippen","year":"2021","unstructured":"Hippen, A. A. et al. miQC: an adaptive probabilistic framework for quality control of single-cell RNA-sequencing data. PLoS Comput. Biol. 17, e1009290 (2021).","journal-title":"PLoS Comput. Biol."},{"key":"4717_CR37","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289\u20131296 (2019).","journal-title":"Nat. Methods"},{"key":"4717_CR38","doi-asserted-by":"publisher","first-page":"979","DOI":"10.12688\/f1000research.73600.1","volume":"10","author":"PL Germain","year":"2021","unstructured":"Germain, P. L., Lun, A., Garcia Meixide, C., Macnair, W. & Robinson, M. D. Doublet identification in single-cell sequencing data using scDblFinder. F1000Res. 10, 979 (2021).","journal-title":"F1000Res."},{"key":"4717_CR39","doi-asserted-by":"publisher","first-page":"eadf4968","DOI":"10.1126\/sciimmunol.adf4968","volume":"8","author":"G Oliveira","year":"2023","unstructured":"Oliveira, G. et al. Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer. Sci. Immunol. 8, eadf4968 (2023).","journal-title":"Sci. Immunol"},{"key":"4717_CR40","doi-asserted-by":"publisher","unstructured":"Zappia, L. & Oshlack, A. Clustering trees: a visualization for evaluating clusterings at multiple resolutions. Gigascience https:\/\/doi.org\/10.1093\/gigascience\/giy083 (2018).","DOI":"10.1093\/gigascience\/giy083"},{"key":"4717_CR41","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41586-022-04682-5","volume":"605","author":"G Oliveira","year":"2022","unstructured":"Oliveira, G. et al. Landscape of helper and regulatory antitumour CD4(+) T cells in melanoma. Nature 605, 532\u2013538 (2022).","journal-title":"Nature"},{"key":"4717_CR42","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst"},{"key":"4717_CR43","doi-asserted-by":"publisher","unstructured":"Korotkevich, G. et al. Fast gene set enrichment analysis. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/060012 (2021).","DOI":"10.1101\/060012"},{"key":"4717_CR44","doi-asserted-by":"crossref","unstructured":"Wickham, H. ggplot2: Elegant Graphics for Data Analysis (Springer, 2016).","DOI":"10.1007\/978-3-319-24277-4_9"},{"key":"4717_CR45","doi-asserted-by":"publisher","unstructured":"Afeyan, A. B., Wu, C. J. & Oliveira, G. Rapid parallel reconstruction and specificity screening of hundreds of T cell receptors. Nat. Protoc. https:\/\/doi.org\/10.1038\/s41596-024-01061-4 (2024).","DOI":"10.1038\/s41596-024-01061-4"},{"key":"4717_CR46","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.annonc.2023.08.004","volume":"34","author":"HA Parsons","year":"2023","unstructured":"Parsons, H. A. et al. Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030. Ann. Oncol. 34, 899\u2013906 (2023).","journal-title":"Ann. Oncol."},{"key":"4717_CR47","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1093\/bioinformatics\/btv710","volume":"32","author":"X Chen","year":"2016","unstructured":"Chen, X. et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics 32, 1220\u20131222 (2016).","journal-title":"Bioinformatics"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04717-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04717-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04717-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:56:23Z","timestamp":1792014983000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04717-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":47,"alternative-id":["4717"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04717-8","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.C.S., J.A.F., B.S., A.V., R.L., C.F., C.R.T., K.T., A.K., S.C., C.S., K.X., P.J., A.C., H.E.S., V.C., W.L., J.T.J., M.R.Y., A.S., S.S., M.H., O.O., H.G., C.C., S.L., N.T., E.H.S., C.K., R.P., G.O. and J.S.M. declare no competing interests. J.K.L. holds equity in Standard BioTools and is on the scientific advisory board for MBQ Pharma. N.H. holds equity in and advises Repertoire Immune Medicines, CytoReason and Danger Bio\/Related Sciences, owns equity and has licensed patents to BioNtech, and receives research funding from Bristol Myers Squibb, Moderna, ResolveM\/JJDC, Takeda and Calico Life Sciences. U.A.M. declares participation in scientific advisory boards: NextCure, AbbVie, Immunogen, Profound Bio, Eisai, the Ovarian Cancer Research Alliance, Tango Therapeutics, Novartis, GSK, Daiichi Sankyo, DayOne Bio and Whitehawk Therapeutics; U.A.M. also reports participation in a data safety-monitoring board: Mural Oncology, Macrogenics, Daiichi Sankyo, AstraZeneca and Symphogen, all unrelated to this work. V.A.A. is a co-inventor of the MAESTRO MRD test, which has been licensed to Exact Sciences and receives research funding from Exact Sciences, which was not involved in this study. V.A.A. is also a co-founder and advisor to Amplifyer Bio. G.G. receives research funds from IBM, Pharmacyclics\/AbbVie, Bayer, Genentech, Calico, Ultima Genomics, Inocras, Google, Kite, AstraZeneca and Novartis and is also an inventor on patent applications filed by the Broad Institute, including those related to MSMuTect, MSMutSig, POLYSOLVER, SignatureAnalyzer-GPU, MSEye, MinimuMM-seq, DLBclass, HapASeg, Tonly2, MSIDetect, TuFEst and ABSOLUTE2. A full list of G.G.\u2019s publicly available patent applications can be requested from the Broad\u2019s legal team at patents@broadinstitute.org. G.G is a founder, consultant, and holds privately held equity in Scorpion Therapeutics; he is also a founder of, and holds privately held equity in Predicta Biosciences; and a consultant and holds privately held equity in Antares Therapeutics. D.B.K. owns equity in Affimed N.V., Agenus, Armata Pharmaceuticals, Breakbio, BioMarin Pharmaceuticals, Celldex Therapeutics, Editas Medicine, Immunitybio, Lexicon Pharmaceuticals, Moderna, PDS Biotechnology, Prime Medicine, Sana Biotechnologies and Viking Therapeutics. D.B.K. is a scientific advisor for Immunitrack, a wholly owned subsidiary of Eli Lilly and Company and Breakbio. P.A.O. has received research funding from and\/or has advised Agenus, Arcturus, Amgen, Armo BioSciences, Array, AstraZeneca\/MedImmune, Bristol-Meyers Squibb, Celldex, CytomX, Evaxion, Immunetune, Imunon, LGChem, Merck, Neon Therapeutics (now BioNTechUS), Novartis, Pharmajet, Phio, Pfizer, Oncorus, Roche\/Genentech, Servier and Xencor. P.A.K. has received grants or contracts from Novartis, AstraZeneca, Pfizer, Eli Lilly, Bayer, Merck, GlaxoSmithKline, Tesaro and Merck KGaA and has received consulting fees for serving on advisory boards from AstraZeneca, Bayer, GlaxoSmithKline, Alkermes, Kadmon, Bristol Myers Squibb, IMV, Repare, Artios, Mersana, Novartis, Cardiff Oncology, Schrodinger, Mural Oncology, Scorpion and Nimbus. C.J.W. is an equity holder of BioNtech and is a scientific advisory board member of Repertoire, Aethon Therapeutics, Nature\u2019s Toolbox and Adventris.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}